In a recent study, similar rates of live birth and other pregnancy outcomes were reported between patients receiving double- vs single-layer uterine closure following cesarean delivery, indicating a lack of superiority from a single method.

A recent study found no significant difference in live birth rates between blastocyst and cleavage stage embryo transfers in women with 4 or more embryos during in vitro fertilization.

In a recent study, infants of mothers with an influenza infection during pregnancy were significantly more likely to experience febrile seizures, but not epilepsy.

In a recent study, the odds of miscarriage, fecundability, and subfertility were significantly increased among patients with a body mass index outside the normal category during the preconception or early-pregnancy period.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A recent study reveals that pregnancy-specific factors influence aspirin pharmacokinetics and pharmacodynamics, suggesting the need for tailored aspirin dosing to optimize outcomes in preventing preeclampsia.

In a recent study, a significant improvement in the average quality-adjusted life years gained was reported following BRCA1 testing during obstetrical prenatal carrier screening.

A recent study shows that adding metronidazole to cefazolin significantly lowers the risk of surgical site infections in gynecologic cancer surgeries, enhancing patient outcomes.

Matthew Nudy, MD, discusses his team's findings on hormone therapy and cardiovascular effects at the 2024 Annual Meeting of the Menopause Society.

In a recent study, very preterm birth rates were reduced during COVID-19 lockdown periods vs prepandemic periods.

In a recent study, reported rates on emergency department utilization for hypertensive disorders of pregnancy and the postpartum period were higher in 2020 than 2006, with rates especially high among non-Hispanic Black, Hispanic, and Asian patients.

Learn how self-advocacy, preparation, and collaboration with doctors can help women gain control over their health and live more fully, free from stigma and shame.

Discover how deepening understanding and providing vetted resources can empower women to reclaim their wellness and navigate the powerful impacts of menopause with confidence.

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

Fezolinetant offers women a groundbreaking, non-hormonal solution to manage menopause symptoms like hot flashes and sleep disturbances, supported by large clinical trials.

A new study highlights gestational hypertension as a significant predictor of cardiovascular disease in menopausal women, challenging previous assumptions about preeclampsia’s role.

Research reveals that environmental exposures and PTSD from Gulf War service significantly increase the likelihood of early menopause, highlighting the need for targeted reproductive health care for women veterans.

Vanessa Muñiz presents research comparing clinical hypnosis and cognitive behavioral therapy for treating hot flashes, revealing that hypnosis significantly reduces frequency and improves quality of life.

Stephanie Faubion, MD, MBA, medical director of the Menopause Society, shares details from her presentation on hormone therapy at the 2024 Annual Meeting of The Menopause Society.

Lauren Streicher, MD, advocates for practical, individualized solutions for postmenopausal sexual dysfunction, emphasizing increased vascularization, stimulation, and addressing related symptoms.

The FDA upped the recommended rate of liver blood tests for patients initiating fezolinetant on the basis of a post-marketing case report involving serious liver injury.

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

The phase 3 OASIS trial presented at the 2024 Annual Meeting of The Menopause Society displayed significant improvements in the frequency of moderate-to-severe vasomotor symptoms among patients receiving elinzanetant.

Low rates of hormone therapy use have been reported among midlife women, stagnating after decreases in the immediate aftermath of the Women’s Health Initiative.